{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:20:47Z","timestamp":1784755247560,"version":"3.55.0"},"reference-count":98,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Adult T-cell leukemia\/lymphoma (ATLL) is a peripheral T-cell lymphoma (PTCL) caused by human T-cell leukemia virus type 1 (HTLV-1). Recent comprehensive genomic analyses have revealed the genomic landscape. One of the important findings of genomic alterations in ATLL is that almost all alterations are subclonal, suggesting that therapeutic strategies targeting a genomic alteration will result in partial effects. Among the identified alterations, genes involved in T-cell receptor signaling and immune escape mechanisms, such as PLCG1, CARD11, and PD-L1 (also known as CD274), are characteristic of ATLL alterations. From a geographic perspective, ATLL patients in Caribbean islands tend to be younger than those in Japan and the landscape differs between the two areas. Additionally, young Japanese ATLL patients frequently have CD28 fusions, compared with unselected Japanese cases. From a clinical perspective, PD-L1 amplification is an independent prognostic factor among every subtype of ATLL case. Recently, genomic analysis using deep sequencing identified a pre-ATLL clone with ATLL-common mutations in HTLV-1 carriers before development, indicating that genomic analysis can stratify cases based on the risks of development and mortality. In addition to genomic alterations, targetable super-enhancers have been identified in ATLL. These data can be leveraged to improve the prognosis of ATLL.<\/jats:p>","DOI":"10.3390\/cancers13081801","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T10:05:21Z","timestamp":1617962721000},"page":"1801","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-0106","authenticated-orcid":false,"given":"Noriaki","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan"},{"name":"Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0736-4679(99)00173-0","article-title":"Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I)","volume":"18","author":"Edlich","year":"2000","journal-title":"J. Emerg. Med."},{"key":"ref_5","first-page":"177","article-title":"Mother-to-child transmission of HTLV-1","volume":"15","author":"Ichimaru","year":"1991","journal-title":"Cancer Detect. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/bcj.2013.57","article-title":"Association between decreasing trend in the mortality of adult T-cell leukemia\/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: Analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"3","author":"Chihara","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fmicb.2019.02235","article-title":"Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_11","first-page":"226","article-title":"Incidence of adult T-cell leukemia\/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan","volume":"49","author":"Tokudome","year":"1989","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ijc.2910450206","article-title":"4th nation-wide study of adult T-cell leukemia\/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features","volume":"45","author":"Tajima","year":"1990","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B","article-title":"Evaluation of adult T-cell leukemia\/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan","volume":"85","author":"Arisawa","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 Infection and ATL in Japan: An Update","volume":"11","author":"Iwanaga","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ijc.2910430618","article-title":"Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers","volume":"43","author":"Kondo","year":"1989","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan","volume":"116","author":"Iwanaga","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1349-7006.2010.01820.x","article-title":"Ethnoepidemiology of HTLV-1 related diseases: Ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal","volume":"102","author":"Sonoda","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1038\/ncomms4393","article-title":"Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers","volume":"5","author":"Nakahata","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1158\/0008-5472.CAN-14-0643","article-title":"Molecular Characterization of Chronic-type Adult T-cell Leukemia\/Lymphoma","volume":"74","author":"Yoshida","year":"2014","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood.2019001815","article-title":"Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions","volume":"135","author":"Yoshida","year":"2020","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/cas.13303","article-title":"Genetic alterations in adult T-cell leukemia\/lymphoma","volume":"108","author":"Kogure","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_24","first-page":"226","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The Genetic Basis of Hepatosplenic T-cell Lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/onc.2010.537","article-title":"Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: Viral infectivity, Tax, HBZ and therapy","volume":"30","author":"Matsuoka","year":"2010","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/01.tp.0000235186.30113.c7","article-title":"Adult T-cell Leukemia Development from a Human T-cell Leukemia Virus Type I Carrier After a Living-Donor Liver Transplantation","volume":"82","author":"Kawano","year":"2006","journal-title":"Transplantation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1600-6143.2012.04037.x","article-title":"Impact of Human T Cell Leukemia Virus Type 1 in Living Donor Liver Transplantation","volume":"12","author":"Yoshizumi","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined Genetic Inactivation of \u03b22-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma","volume":"20","author":"Lieu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/ijc.22536","article-title":"Regulatory T-cell function of adult T-cell leukemia\/lymphoma cells","volume":"120","author":"Yano","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","article-title":"Expression of FoxP3, a key molecule in CD4+ CD25+ regulatory T cells, in adult T-cell leukaemia\/lymphoma cells","volume":"126","author":"Karube","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2403965","article-title":"FOXP3, a selective marker for a subset of adult T-cell leukaemia\/lymphoma","volume":"19","author":"Roncador","year":"2005","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","article-title":"Targeting the HTLV-I-Regulated BATF3\/IRF4 Transcriptional Network in Adult T Cell Leukemia\/Lymphoma","volume":"34","author":"Nakagawa","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.12688\/f1000research.17479.1","article-title":"40 years of the human T-cell leukemia virus: Past, present, and future","volume":"8","author":"Tagaya","year":"2019","journal-title":"F1000Research"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11864-014-0321-5","article-title":"Incidence of Adult T-Cell Leukemia\/Lymphoma in Nonendemic Areas","volume":"16","author":"Yoshida","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-Cell Leukemia: A Review of Epidemiological Evidence","volume":"3","author":"Iwanaga","year":"2012","journal-title":"Front. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JGO.19.00208","article-title":"Clinical Characteristics and Outcomes of Caribbean Patients with Adult T-Cell Lymphoma\/Leukemia at Two Affiliated New York City Hospitals","volume":"6","author":"Chiu","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: A nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8890502","article-title":"A Rare CD4\u2212CD8+ Adult T-Cell Leukemia\/Lymphoma with Unique Molecular Mutations: A Case Report with Literature Review","volume":"2020","author":"Choudhuri","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hashemi Zonouz, T., Abdulbaki, R., Bandyopadhyay, B., and Nava, V. (2021). Novel Mutations in a Lethal Case of Lymphomatous Adult T Cell Lymphoma with Cryptic Myocardial Involvement. Curr. Oncol., 28.","DOI":"10.3390\/curroncol28010079"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-018-06485-7","article-title":"Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome","volume":"9","author":"Rusch","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","article-title":"Genomic subtyping and therapeutic targeting of acute erythroleukemia","volume":"51","author":"Iacobucci","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1349-7006.2007.00456.x","article-title":"Pathological features of diseases associated with human T-cell leukemia virus type I","volume":"98","author":"Ohshima","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","article-title":"Array Comparative Genomic Hybridization Analysis of PTCL-U Reveals a Distinct Subgroup with Genetic Alterations Similar to Lymphoma-Type Adult T-Cell Leukemia\/Lymphoma","volume":"15","author":"Nakagawa","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1182\/blood-2010-12-327791","article-title":"Clonal evolution of adult T-cell leukemia\/lymphoma takes place in the lymph nodes","volume":"117","author":"Umino","year":"2011","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cam4.34","article-title":"Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations","volume":"1","author":"Yoshida","year":"2012","journal-title":"Cancer Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ni823","article-title":"PKC-\u03b2 controls I\u03baB kinase lipid raft recruitment and activation in response to BCR signaling","volume":"3","author":"Su","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri2476","article-title":"GATA3 and the T-cell lineage: Essential functions before and after T-helper-2-cell differentiation","volume":"9","author":"Ho","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/2159-8290.CD-19-0471","article-title":"GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia","volume":"9","author":"Belver","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia\/Lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","article-title":"Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma","volume":"130","author":"Katsuya","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3324\/haematol.2018.205567","article-title":"Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia\/lymphoma","volume":"104","author":"Takeuchi","year":"2019","journal-title":"Haematologica"},{"key":"ref_64","first-page":"377","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells after Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2010.028605","article-title":"Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy","volume":"96","author":"Sasaki","year":"2011","journal-title":"Haematologica"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","article-title":"Polycomb-Mediated Loss of miR-31 Activates NIK-Dependent NF-\u03baB Pathway in Adult T Cell Leukemia and Other Cancers","volume":"21","author":"Yamagishi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","article-title":"PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma","volume":"128","author":"Miyoshi","year":"2016","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/his.13461","article-title":"Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia\/lymphoma","volume":"72","author":"Asano","year":"2018","journal-title":"Histopathology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2017-11-815472","article-title":"Clinicogenetic risk modeling in ATL","volume":"131","author":"Yoshida","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood.2019002665","article-title":"Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis","volume":"135","author":"Rowan","year":"2020","journal-title":"Blood"},{"key":"ref_75","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/path.4699","article-title":"CCR4frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis","volume":"238","author":"Yoshida","year":"2016","journal-title":"J. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2169\/internalmedicine.2513-18","article-title":"Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012\u20132018)","volume":"58","author":"Kawano","year":"2019","journal-title":"Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia\u2013Lymphoma after PD-1 Inhibitor Therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2012.00245","article-title":"The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function","volume":"3","author":"Han","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.2019002639","article-title":"Feed-forward regulatory loop driven by IRF4 and NF-\u03baB in adult T-cell leukemia\/lymphoma","volume":"135","author":"Wong","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia\/Lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","volume":"355","author":"List","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Fink","year":"2015","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-Enhancers in the Control of Cell Identity and Disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers","volume":"153","author":"Hoke","year":"2013","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","article-title":"CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer","volume":"159","author":"Chipumuro","year":"2014","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood-2017-06-792184","article-title":"Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1801\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:59:13Z","timestamp":1760363953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":98,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081801"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081801","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]}}}